AAAAAA
Results:
1-15
|
Results: 15
Authors:
Massy, ZA
Swan, SK
Citation: Za. Massy et Sk. Swan, Cyclooxygenase-2 and atherosclerosis: friend or foe?, NEPH DIAL T, 16(12), 2001, pp. 2286-2289
Authors:
Swan, SK
Brater, DC
Citation: Sk. Swan et Dc. Brater, Cyclooxygenase-2 inhibition and renal function - Response, ANN INT MED, 134(11), 2001, pp. 1078-1078
Authors:
Lewis, MJ
Swan, SK
Citation: Mj. Lewis et Sk. Swan, The generation of non-dextran intravenous iron: Is iron dextran obsolete?, SEMIN DIAL, 13(1), 2000, pp. 9-10
Authors:
Swan, SK
St Peter, JV
Lambrecht, LJ
Hursting, MJ
Citation: Sk. Swan et al., Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects, PHARMACOTHE, 20(7), 2000, pp. 756-770
Authors:
Swan, SK
Hursting, MJ
Citation: Sk. Swan et Mj. Hursting, The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction, PHARMACOTHE, 20(3), 2000, pp. 318-329
Authors:
Townsend, RR
Cohen, DL
Katholi, R
Swan, SK
Davies, BE
Bensel, K
Lambrecht, L
Parker, J
Citation: Rr. Townsend et al., Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency, AM J KIDNEY, 36(6), 2000, pp. 1207-1212
Authors:
St Peter, JV
Lambrecht, LJ
Gunderson, BW
Andersen, SA
Gallagher, SC
Swan, SK
Citation: Jv. St Peter et al., Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function, J CLIN PHAR, 40(12), 2000, pp. 1470-1475
Authors:
Swan, SK
Rudy, DW
Lasseter, KC
Ryan, CF
Buechel, KL
Lambrecht, LJ
Pinto, MB
Dilzer, SC
Obrda, O
Sundblad, KJ
Gumbs, CP
Ebel, DL
Quan, H
Larson, PJ
Schwartz, JI
Musliner, TA
Gertz, BJ
Brater, DC
Yao, SL
Citation: Sk. Swan et al., Effect of cyclooxygenase-2 inhibition on renal function in elderly personsreceiving a low-salt diet - A randomized, controlled trial, ANN INT MED, 133(1), 2000, pp. 1-9
Authors:
Swan, SK
Baker, JF
Free, R
Tucker, RM
Barron, B
Barr, R
Seltzer, S
Gazelle, GS
Maravilla, KR
Barr, W
Stevens, GR
Lambrecht, LJ
Pierro, JA
Citation: Sk. Swan et al., Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function, J MAGN R I, 9(2), 1999, pp. 317-321
Authors:
Anjum, S
Swan, SK
Lambrecht, LJ
Radwanski, E
Cutler, DL
Affrime, MB
Halstenson, CE
Citation: S. Anjum et al., Pharmacokinetics of flutamide in patients with renal insufficiency, BR J CL PH, 47(1), 1999, pp. 43-47
Authors:
Swan, SK
Hoyumpa, AM
Merritt, GJ
Citation: Sk. Swan et al., Review article: the pharmacokinetics of rabeprazole in health and disease, ALIM PHARM, 13, 1999, pp. 11-17
Authors:
Keane, WF
Swan, SK
Grimes, I
Humphries, TJ
Citation: Wf. Keane et al., Rabeprazole: Pharmacokinetics and tolerability in patients with stable, end-stage renal failure, J CLIN PHAR, 39(9), 1999, pp. 927-933
Authors:
Andersen, SR
Lambrecht, LJ
Swan, SK
Cutler, DL
Radwanski, E
Affrime, MB
Garaud, JJ
Citation: Sr. Andersen et al., Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function, J CLIN PHAR, 39(10), 1999, pp. 1015-1020
Authors:
Mathur, VS
Swan, SK
Lambrecht, LJ
Anjum, S
Fellmann, J
McGuire, D
Epstein, M
Luther, RR
Citation: Vs. Mathur et al., The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects, CRIT CARE M, 27(9), 1999, pp. 1832-1837
Authors:
Swan, SK
Lambrecht, LJ
Townsend, R
Davies, BE
McCloud, S
Parker, JR
Bensel, K
LaFrance, ND
Citation: Sk. Swan et al., Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment, INV RADIOL, 34(7), 1999, pp. 443-448
Risultati:
1-15
|